{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:29:44Z","timestamp":1761895784937},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T00:00:00Z","timestamp":1389052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s11899-013-0192-z","type":"journal-article","created":{"date-parts":[[2014,1,6]],"date-time":"2014-01-06T03:34:25Z","timestamp":1388979265000},"page":"1-8","source":"Crossref","is-referenced-by-count":10,"title":["Molecular Monitoring"],"prefix":"10.1007","volume":"9","author":[{"given":"Simona","family":"Soverini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,7]]},"reference":[{"issue":"Suppl 1","key":"192_CR1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/10428199309047861","volume":"11","author":"NC Cross","year":"1993","unstructured":"Cross NC, Feng L, Bungey J, et al. Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction. Leuk Lymphoma. 1993;11 Suppl 1:39\u201343.","journal-title":"Leuk Lymphoma"},{"key":"192_CR2","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.V82.6.1929.1929","volume":"82","author":"NC Cross","year":"1993","unstructured":"Cross NC, Feng L, Chase A, et al. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood. 1993;82:1929\u201336.","journal-title":"Blood"},{"key":"192_CR3","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1101\/gr.6.10.986","volume":"6","author":"CA Heid","year":"1996","unstructured":"Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR. Genome Res. 1996;6:986\u201394.","journal-title":"Genome Res"},{"key":"192_CR4","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2141.1998.00823.x","volume":"102","author":"E Mensink","year":"1998","unstructured":"Mensink E, van de Locht A, Schattenberg A, et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Br J Haematol. 1998;102:768\u201374.","journal-title":"Br J Haematol"},{"key":"192_CR5","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/sj.leu.2401566","volume":"13","author":"M Emig","year":"1999","unstructured":"Emig M, Saussele S, Wittor H, et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia. 1999;13:1825\u201332.","journal-title":"Leukemia"},{"key":"192_CR6","first-page":"252","volume":"86","author":"M Amabile","year":"2001","unstructured":"Amabile M, Giannini B, Testoni N, et al. Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. Haematologica. 2001;86:252\u20139.","journal-title":"Haematologica"},{"key":"192_CR7","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","volume":"17","author":"S Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 2003;17:2401\u20139.","journal-title":"Leukemia"},{"key":"192_CR8","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1038\/sj.leu.2403157","volume":"17","author":"MC Muller","year":"2003","unstructured":"Muller MC, Gattermann N, Lahaye T, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha\/ara-C. Leukemia. 2003;17:2392\u2013400.","journal-title":"Leukemia"},{"key":"192_CR9","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384. This is the most recent version of the ELN recommendations for the treatment of CML patients, incorporating molecular response milestones at different timepoints into the definition of optimal response, failure and warning.","journal-title":"Blood"},{"key":"192_CR10","author":"FX Mahon","year":"2013","unstructured":"Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res. 2013. doi: 10.1158\/1078-0432 .","journal-title":"Clin Cancer Res"},{"key":"192_CR11","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029\u201335.","journal-title":"Lancet Oncol"},{"key":"192_CR12","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","volume":"97","author":"N Takahashi","year":"2012","unstructured":"Takahashi N, Kyo T, Maeda Y, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012;97:903\u20136.","journal-title":"Haematologica"},{"key":"192_CR13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515\u201322.","journal-title":"Blood"},{"key":"192_CR14","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17:2318\u201357.","journal-title":"Leukemia"},{"key":"192_CR15","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","volume":"17","author":"E Beillard","year":"2003","unstructured":"Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia. 2003;17:2474\u201386.","journal-title":"Leukemia"},{"key":"192_CR16","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","volume":"20","author":"S Branford","year":"2006","unstructured":"Branford S, Cross NC, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 2006;20:1925\u201330.","journal-title":"Leukemia"},{"key":"192_CR17","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423\u201332.","journal-title":"N Engl J Med"},{"key":"192_CR18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28\u201337.","journal-title":"Blood"},{"key":"192_CR19","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","volume":"112","author":"S Branford","year":"2008","unstructured":"Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112:3330\u20138.","journal-title":"Blood"},{"key":"192_CR20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.beha.2009.04.001","volume":"22","author":"NC Cross","year":"2009","unstructured":"Cross NC. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009;22:355\u201365.","journal-title":"Best Pract Res Clin Haematol"},{"key":"192_CR21","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","volume":"23","author":"MC Muller","year":"2009","unstructured":"Muller MC, Cross NC, Erben P, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia. 2009;23:1957\u201363.","journal-title":"Leukemia"},{"key":"192_CR22","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s10147-011-0328-x","volume":"17","author":"C Yoshida","year":"2012","unstructured":"Yoshida C, Fletcher L, Ohashi K, et al. Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan. Int J Clin Oncol. 2012;17:584\u20139.","journal-title":"Int J Clin Oncol"},{"key":"192_CR23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000334716","volume":"127","author":"P Balasubramanian","year":"2012","unstructured":"Balasubramanian P, Chendamarai E, Markose P, et al. International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: first report from India. Acta Haematol. 2012;127:135\u201342.","journal-title":"Acta Haematol"},{"key":"192_CR24","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1182\/blood-2010-06-291641","volume":"116","author":"HE White","year":"2010","unstructured":"White HE, Matejtschuk P, Rigsby P, et al. Establishment of the first world health organization international genetic reference panel for quantitation of BCR-ABL mRNA. Blood. 2010;116:e111\u20137.","journal-title":"Blood"},{"key":"192_CR25","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1373\/clinchem.2012.196477","volume":"59","author":"HE White","year":"2013","unstructured":"White HE, Hedges J, Bendit I, et al. Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. Clin Chem. 2013;59:938\u201348.","journal-title":"Clin Chem"},{"key":"192_CR26","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2004-02-0711","volume":"104","author":"HM Kantarjian","year":"2004","unstructured":"Kantarjian HM, Cortes JE, O'Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004;104:1979\u201388.","journal-title":"Blood"},{"key":"192_CR27","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","volume":"103","author":"H Kantarjian","year":"2004","unstructured":"Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873\u20138.","journal-title":"Blood"},{"key":"192_CR28","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","volume":"11","author":"J Cortes","year":"2005","unstructured":"Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005;11:3425\u201332.","journal-title":"Clin Cancer Res"},{"key":"192_CR29","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809\u201320.","journal-title":"Blood"},{"key":"192_CR30","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041\u201351.","journal-title":"J Clin Oncol"},{"key":"192_CR31","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2009-11-255109","volume":"116","author":"M Sobrinho-Simoes","year":"2010","unstructured":"Sobrinho-Simoes M, Wilczek V, Score J, et al. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood. 2010;116:1329\u201335.","journal-title":"Blood"},{"key":"192_CR32","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","volume":"24","author":"DM Ross","year":"2010","unstructured":"Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010;24:1719\u201324.","journal-title":"Leukemia"},{"key":"192_CR33","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NC Cross","year":"2012","unstructured":"Cross NC, White HE, Muller MC, et al. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26:2172\u20135. The rationale and novel terminology for quantitation and definition of deep molecular response levels in CML patients.","journal-title":"Leukemia"},{"key":"192_CR34","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.leukres.2006.03.011","volume":"30","author":"M Breccia","year":"2006","unstructured":"Breccia M, Diverio D, Pane F, et al. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon. Leuk Res. 2006;30:1577\u20139.","journal-title":"Leuk Res"},{"key":"192_CR35","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1080\/10428190802043903","volume":"49","author":"D Verma","year":"2008","unstructured":"Verma D, Kantarjian H, Jain N, et al. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. Leuk Lymphoma. 2008;49:1399\u2013402.","journal-title":"Leuk Lymphoma"},{"key":"192_CR36","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.leukres.2008.11.027","volume":"33","author":"S Guastafierro","year":"2009","unstructured":"Guastafierro S, Falcone U, Celentano M, et al. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR\/ABL? A case report and a review of the literature. Leuk Res. 2009;33:1079\u201381.","journal-title":"Leuk Res"},{"key":"192_CR37","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2\u00a0years. Blood. 2007;109:58\u201360.","journal-title":"Blood"},{"key":"192_CR38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1532\/IJH97.06187","volume":"85","author":"S Okabe","year":"2007","unstructured":"Okabe S, Tauchi T, Ishii Y, et al. Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy. Int J Hematol. 2007;85:173\u20134.","journal-title":"Int J Hematol"},{"key":"192_CR39","first-page":"979","volume":"90","author":"S Merante","year":"2005","unstructured":"Merante S, Orlandi E, Bernasconi P, et al. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica. 2005;90:979\u201381.","journal-title":"Haematologica"},{"key":"192_CR40","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1016\/j.ejca.2013.06.018","volume":"49","author":"N Thielen","year":"2013","unstructured":"Thielen N, van der Holt B, Cornelissen JJ, et al. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer. 2013;49:3242\u20136.","journal-title":"Eur J Cancer"},{"key":"192_CR41","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.leukres.2013.07.029","volume":"37","author":"MJ Mauro","year":"2013","unstructured":"Mauro MJ. Striving to achieve safe, permanent treatment discontinuation in chronic myeloid leukemia. Leuk Res. 2013;37:1395\u2013403.","journal-title":"Leuk Res"},{"key":"192_CR42","doi-asserted-by":"crossref","unstructured":"Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121:4439\u201342.","DOI":"10.1182\/blood-2013-03-490003"},{"key":"192_CR43","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2141.2011.08603.x","volume":"153","author":"L Foroni","year":"2011","unstructured":"Foroni L, Wilson G, Gerrard G, et al. Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia. Br J Haematol. 2011;153:179\u201390. Consensus best practice guidelines for RQ-PCR testing, data interpretation and reporting in CML.","journal-title":"Br J Haematol"},{"key":"192_CR44","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","volume":"120","author":"L Wang","year":"2003","unstructured":"Wang L, Pearson K, Ferguson JE, et al. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol. 2003;120:990\u20139.","journal-title":"Br J Haematol"},{"key":"192_CR45","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26:2096\u2013102.","journal-title":"Leukemia"},{"key":"192_CR46","volume-title":"Early response (molecular and cytogenetic), 3-year data and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase: exploratory analysis of DASISION 3-year data [abstract 1675]","author":"G Saglio","year":"2012","unstructured":"Saglio G, Kantarjian H, Shah NP, et al. Early response (molecular and cytogenetic), 3-year data and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase: exploratory analysis of DASISION 3-year data [abstract 1675]. Atlanta: Presented at the 49th Annual Meeting of the American Society of Hematology; 2012. December 8\u201311. 2012."},{"key":"192_CR47","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Hughes T, Saglio G, et al. Outcome of patients with chronic myeloid leukemia in chronic phase based on early molecular response and factors associated with early response: 4-year follow-up of data from ENESTnd (evaluating nilotinib efficacy and safety in clinical trials newly diagnosed patients) [abstract 167]. Presented at the 49th Annual Meeting of the American Society of Hematology. Atlanta, USA; 2012, December 8\u201311. 2012.","DOI":"10.1182\/blood.V120.21.167.167"},{"key":"192_CR48","volume-title":"Assessment of early molecular response as a predictor of long-term clinical outcomes in the phase 3 BELA study [abstract 69]","author":"T Brummendorf","year":"2012","unstructured":"Brummendorf T, Kantarjian H, Gambacorti Passerini C, et al. Assessment of early molecular response as a predictor of long-term clinical outcomes in the phase 3 BELA study [abstract 69]. Atlanta: Presented at the 49th Annual Meeting of the American Society of Hematology; 2012. December 8\u201311. 2012."},{"key":"192_CR49","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3\u00a0months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30:232\u20138.","journal-title":"J Clin Oncol"},{"key":"192_CR50","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","volume":"30","author":"S Branford","year":"2012","unstructured":"Branford S, Kim DW, Soverini S, et al. Initial molecular response at 3\u00a0months may predict both response and event-free survival at 24\u00a0months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol. 2012;30:4323\u20139.","journal-title":"J Clin Oncol"},{"key":"192_CR51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2012-01-407486","volume":"120","author":"D Marin","year":"2012","unstructured":"Marin D, Hedgley C, Clark RE, et al. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood. 2012;120:291\u20134.","journal-title":"Blood"},{"key":"192_CR52","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","volume":"121","author":"P Jain","year":"2013","unstructured":"Jain P, Kantarjian H, Nazha A, et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013;121:4867\u201374.","journal-title":"Blood"},{"key":"192_CR53","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1182\/blood.V87.6.2588.bloodjournal8762588","volume":"87","author":"JG Zhang","year":"1996","unstructured":"Zhang JG, Lin F, Chase A, et al. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation. Blood. 1996;87:2588\u201393.","journal-title":"Blood"},{"key":"192_CR54","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2141.2009.08071.x","volume":"149","author":"PA Bartley","year":"2010","unstructured":"Bartley PA, Martin-Harris MH, Budgen BJ, et al. Rapid isolation of translocation breakpoints in chronic myeloid and acute promyelocytic leukaemia. Br J Haematol. 2010;149:231\u20136.","journal-title":"Br J Haematol"},{"key":"192_CR55","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1111\/j.1751-553X.2010.01236.x","volume":"32","author":"PA Bartley","year":"2010","unstructured":"Bartley PA, Ross DM, Latham S, et al. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. Int J Lab Hematol. 2010;32:e222\u20138.","journal-title":"Int J Lab Hematol"},{"key":"192_CR56","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3109\/10428194.2011.555569","volume":"52","author":"HG Goh","year":"2011","unstructured":"Goh HG, Lin M, Fukushima T, et al. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma. 2011;52:896\u2013904.","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"192_CR57","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1373\/clinchem.2013.214742","volume":"59","author":"JF Huggett","year":"2013","unstructured":"Huggett JF, Whale A. Digital PCR as a novel technology and its potential implications for molecular diagnostics. Clin Chem. 2013;59(12):1691\u20133.","journal-title":"Clin Chem"},{"key":"192_CR58","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/PAT.0b013e32834e4203","volume":"44","author":"M McNiven","year":"2012","unstructured":"McNiven M, Talaulikar D. Establishment of a conversion factor for the Cepheid GeneXpert BCR-ABL assay. Pathology. 2012;44:55\u20137.","journal-title":"Pathology"},{"key":"192_CR59","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3324\/haematol.2010.034389","volume":"96","author":"JM Cayuela","year":"2011","unstructured":"Cayuela JM, Macintyre E, Darlington M, et al. Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost? Haematologica. 2011;96:664\u201371.","journal-title":"Haematologica"},{"key":"192_CR60","doi-asserted-by":"crossref","first-page":"947","DOI":"10.5858\/2007-131-947-QAOTBT","volume":"131","author":"SD Dufresne","year":"2007","unstructured":"Dufresne SD, Belloni DR, Levy NB, et al. Quantitative assessment of the BCR-ABL transcript using the Cepheid Xpert BCR-ABL Monitor assay. Arch Pathol Lab Med. 2007;131:947\u201350.","journal-title":"Arch Pathol Lab Med"},{"key":"192_CR61","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00277-012-1468-4","volume":"91","author":"CE Lopez-Jorge","year":"2012","unstructured":"Lopez-Jorge CE, Gomez-Casares MT, Jimenez-Velasco A, et al. Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns. Ann Hematol. 2012;91:1245\u201350.","journal-title":"Ann Hematol"},{"key":"192_CR62","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1373\/clinchem.2007.085472","volume":"53","author":"ES Winn-Deen","year":"2007","unstructured":"Winn-Deen ES, Helton B, Van Atta R, et al. Development of an integrated assay for detection of BCR-ABL RNA. Clin Chem. 2007;53:1593\u2013600.","journal-title":"Clin Chem"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-013-0192-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-013-0192-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-013-0192-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T15:30:06Z","timestamp":1647876606000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-013-0192-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,7]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["192"],"URL":"https:\/\/doi.org\/10.1007\/s11899-013-0192-z","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,7]]}}}